Evotec and Novo Nordisk form strategic research alliance in diabetes and obesity
Evotec AG today announced a strategic alliance with Novo Nordisk to discover and develop novel small molecule therapies to treat patients suffering from diabetes and obesity as well as co morbidities such as nonalcoholic steatohepatitis (“NASH”), cardiovascular diseases, and diabetic kidney disease.
28 February 2020
Health Tech Living Lab Summit (Tallinn)
22 October 2019
MEDICA (Düsseldorf, Germany)
3 September 2019
Healthcare Business Summit (Portugal)